Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04252118|
Recruitment Status : Recruiting
First Posted : February 5, 2020
Last Update Posted : February 11, 2020
|Condition or disease||Intervention/treatment||Phase|
|2019 Novel Coronavirus Pneumonia||Biological: MSCs||Phase 1|
2019-nCoV infection has become an urgent public health event in China. As of 24:00 on January 26, 2020, there are 2744 confirmed cases and 461 severe cases in China, the number is still increasing. There is currently no vaccine and no specific antiviral treatment recommended for 2019-nCoV infection. About 20% of the patients were severe and some died of respiratory failure or multiple organ failure. Therefore, it is urgent to find a safe and effective therapeutic approach to pneumonia patients infected with 2019-nCoV.
In the last year, the promising features of mesenchymal stem cells (MSCs), including their regenerative properties and ability to differentiate into diverse cell lineages, have generated great interest among researchers whose work has offered intriguing perspectives on cell-based therapies for various diseases. These findings seem to highlight that the beneficial effect of MSC-based treatment could be principally due by the immunomodulation and regenerative potential of these cells. The investigators found that infusions of UC-MSC significantly improved liver function in decompensated liver cirrhosis and primary biliary cirrhosis (PBC) patients, increased the survival rate in acute-on-chronic liver failure (ACLF) patients . MSCs could significantly reduce the pathological changes of lung and inhibit the cell-mediated immune inflammatory response induced by influenza virus in animal model .
The purpose of this study is to investigate safety and efficiency of MSCs in treating pneumonia patients infected with 2019-nCoV. This multicenter trial will recruit 40 patients. 20 patients received i.v. transfusion one round (3 times) of 1.5-3.0*10E6 cells/kg of MSCs as the treated group, all of them received the conventional treatment. In addition, the equal 20 patients received conventional treatment were used as control. The clinical symptoms, pulmonary imaging, side effects, 28-days mortality, immunological characteristics (immune cells, inflammatory factors, etc.) will be evaluated during the 90 days follow up.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With 2019 Novel Coronavirus|
|Actual Study Start Date :||February 1, 2020|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2021|
Experimental: MSCs Treatment Group
Conventional treatment plus MSCs Participants will receive conventional treatment plus 3 times of MSCs(0.5-1.0*10E6 MSCs/kg body weight intravenously at Day 0, Day 3, Day 6).
3 times of MSCs(0.5-1.0*10E6 MSCs/kg body weight intravenously at Day 0, Day 3, Day 6).
No Intervention: Conventional Control Group
Without MSCs Therapy but conventional treatment should be received.
- Size of lesion area by chest radiograph [ Time Frame: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 28 ]Evaluation of Pneumonia Improvement
- Improvement of Clinical symptoms including duration of fever and respiratory frequency [ Time Frame: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 28 ]Evaluation of Pneumonia Improvement
- Side effects in the MSCs treatment group [ Time Frame: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 28 and Day 90 ]Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Time of nucleic acid turning negative [ Time Frame: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 28 and Day 90 ]Marker for 2019-nCoV
- Rate of mortality within 28-days [ Time Frame: Day 28 ]Marker for efficacy of treatment
- CD4+ and CD8+ T celll count [ Time Frame: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 28 and Day 90 ]Marker of Immunological function
- Alanine aminotransferase [ Time Frame: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 28 and Day 90 ]Markers of organ function
- C-reactive protein [ Time Frame: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 28 and Day 90 ]Markers of Infection
- Creatine kinase [ Time Frame: At Baseline , Day 3, Day 6, Day 10, Day 14, Day 28 and Day 90 ]Markers of organ function
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04252118
|Contact: Lei Shi, MD,PhDfirstname.lastname@example.org|
|Contact: Fusheng Wang, MD,PhDemail@example.com|
|Beijing 302 Military Hospital of China||Recruiting|
|Beijing, China, 100039|
|Contact: Lei Shi, MD, PhD 86-10-66933333 firstname.lastname@example.org|